Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

The direct effect of Focal Adhesion Kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis

Authors: Vita M Golubovskaya, Min Zheng, Li Zhang, Jian-Liang Li, William G Cance

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays an important role in survival signaling. FAK has been shown to be overexpressed in breast cancer tumors at early stages of tumorigenesis.

Methods

To study the direct effect of FAK on breast tumorigenesis, we developed Tet-ON (tetracycline-inducible) system of MCF-7 breast cancer cells stably transfected with FAK or dominant-negative, C-terminal domain of FAK (FAK-CD), and also FAKsiRNA with silenced FAK MCF-7 stable cell line. Increased expression of FAK in isogenic Tet-inducible MCF-7 cells caused increased cell growth, adhesion and soft agar colony formation in vitro, while expression of dominant-negative FAK inhibitor caused inhibition of these cellular processes. To study the role of induced FAK and FAK-CD in vivo, we inoculated these Tet-inducible cells in nude mice to generate tumors in the presence or absence of doxycycline in the drinking water. FAKsiRNA-MCF-7 cells were also injected into nude mice to generate xenograft tumors.

Results

Induction of FAK resulted in significant increased tumorigenesis, while induced FAK-CD resulted in decreased tumorigenesis. Taq Man Low Density Array assay demonstrated specific induction of FAKmRNA in MCF-7-Tet-ON-FAK cells. DMP1, encoding cyclin D binding myb-like protein 1 was one of the genes specifically affected by Tet-inducible FAK or FAK-CD in breast xenograft tumors. In addition, silencing of FAK in MCF-7 cells with FAK siRNA caused increased cell rounding, decreased cell viability in vitro and inhibited tumorigenesis in vivo. Importantly, Affymetrix microarray gene profiling analysis using Human Genome U133A GeneChips revealed >4300 genes, known to be involved in apoptosis, cell cycle, and adhesion that were significantly down- or up-regulated (p < 0.05) by FAKsiRNA.

Conclusion

Thus, these data for the first time demonstrate the direct effect of FAK expression and function on MCF-7 breast cancer tumorigenesis in vivo and reveal specific expression of genes affected by silencing of FAK.
Appendix
Available only for authorised users
Literature
1.
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT: pp125fak a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA. 1992, 89 (11): 5192-5196. 10.1073/pnas.89.11.5192.CrossRefPubMedPubMedCentral
2.
Burridge K, Turner CE, Romer LH: Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol. 1992, 119 (4): 893-903. 10.1083/jcb.119.4.893.CrossRefPubMed
3.
Kornberg LJ, Earp HS, Turner CE, Prockop C, Juliano RL: Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins. Proc Natl Acad Sci USA. 1991, 88 (19): 8392-8396. 10.1073/pnas.88.19.8392.CrossRefPubMedPubMedCentral
4.
Guan JL, Shalloway D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 1992, 358 (6388): 690-692. 10.1038/358690a0.CrossRefPubMed
5.
Hanks SK, Calalb MB, Harper MC, Patel SK: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci USA. 1992, 89 (18): 8487-8491. 10.1073/pnas.89.18.8487.CrossRefPubMedPubMedCentral
6.
Zachary I, Rozengurt E: Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell. 1992, 71 (6): 891-894. 10.1016/0092-8674(92)90385-P.CrossRefPubMed
7.
McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC: The role of focal-adhesion kinase in cancer – a new therapeutic opportunity. Nat Rev Cancer. 2005, 5 (7): 505-515. 10.1038/nrc1647.CrossRefPubMed
8.
Mitra SK, Lim ST, Chi A, Schlaepfer DD: Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene. 2006, 25 (32): 4429-4440. 10.1038/sj.onc.1209482.CrossRefPubMed
9.
van Nimwegen MJ, Verkoeijen S, van Buren L, Burg D, van de Water B: Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res. 2005, 65 (11): 4698-4706. 10.1158/0008-5472.CAN-04-4126.CrossRefPubMed
10.
Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, Alaoui-Jamali MA: Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol. 2008, 173 (5): 1540-1550. 10.2353/ajpath.2008.080292.CrossRefPubMedPubMedCentral
11.
Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ: Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol. 2008, 173 (5): 1551-1565. 10.2353/ajpath.2008.080308.CrossRefPubMedPubMedCentral
12.
Reynolds AB, Roesel DJ, Kanner SB, Parsons JT: Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol. 1989, 9 (2): 629-638.CrossRefPubMedPubMedCentral
13.
Cobb BS, Schaller MD, Leu TH, Parsons JT: Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biology. 1994, 14 (1): 147-155.CrossRef
14.
Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ, Cance WG: Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncology. 1996, 3 (1): 100-105. 10.1007/BF02409059.CrossRef
15.
Agochiya M, Brunton VG, Owens DW, Parkinson EK, Paraskeva C, Keith WN, Frame MC: Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene. 1999, 18 (41): 5646-5653. 10.1038/sj.onc.1202957.CrossRefPubMed
16.
Xu LH, Owens LV, Sturge GC, Yang X, Liu ET, Craven RJ, Cance WG: Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ. 1996, 7 (4): 413-418.PubMed
17.
Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY: Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996, 134 (3): 793-799. 10.1083/jcb.134.3.793.CrossRefPubMed
18.
Crouch DH, Fincham VJ, Frame MC: Targeted proteolysis of the focal adhesion kinase pp125 FAK during c-MYC-induced apoptosis is suppressed by integrin signalling. Oncogene. 1996, 12 (12): 2689-2696.PubMed
19.
Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD: Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem. 1997, 272 (41): 26056-26061. 10.1074/jbc.272.41.26056.CrossRefPubMed
20.
Xu LH, Yang XH, Bradham CA, Brenner DA, Baldwin AS, Craven RJ, Cance WG: The focal adhesion kinase suppresses transformation-associated, anchorage-Independent apoptosis in human breast cancer cells. J Biol Chem. 2000, 275: 30597-30604. 10.1074/jbc.M910027199.CrossRefPubMed
21.
Park HB, Golubovskaya V, Xu L, Yang X, Lee JW, Scully S, Craven RJ, Cance WG: Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells. Biochem J. 2004, 378 (Pt 2): 559-567. 10.1042/BJ20031392.CrossRefPubMedPubMedCentral
22.
Golubovskaya VM, Gross S, Kaur AS, Wilson RI, Xu LH, Yang XH, Cance WG: Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol Cancer Res. 2003, 1 (10): 755-764.PubMed
23.
Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance WG: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Research. 1995, 55 (13): 2752-2755.PubMed
24.
Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S, Xu L: Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res. 2000, 6 (6): 2417-2423.PubMed
25.
Lightfoot HM, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, Craven RJ, Cance WG: Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat. 2004, 88 (2): 109-116. 10.1007/s10549-004-1022-8.CrossRefPubMed
26.
Huang YD, Zhang S: Focal adhesion kinase expression and angiogenesis in breast carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2007, 27 (9): 1370-1373.PubMed
27.
Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, Muller WJ: Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA. 2007, 104 (51): 20302-20307. 10.1073/pnas.0710091104.CrossRefPubMedPubMedCentral
28.
Golubovskaya V, Beviglia L, Xu LH, Earp HS, Craven R, Cance W: Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem. 2002, 277 (41): 38978-38987. 10.1074/jbc.M205002200.CrossRefPubMed
29.
Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ, et al: High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol. 2005, 18 (10): 1289-1294. 10.1038/modpathol.3800424.CrossRefPubMed
30.
Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5 (10): 80-85. 10.1186/gb-2004-5-10-r80.CrossRef
31.
Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19 (2): 185-193. 10.1093/bioinformatics/19.2.185.CrossRefPubMed
32.
Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK: Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics. 2003, 19 (15): 1945-1951. 10.1093/bioinformatics/btg264.CrossRefPubMed
33.
Garces CA, Kurenova EV, Golubovskaya VM, Cance WG: Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res. 2006, 66 (3): 1446-1454. 10.1158/0008-5472.CAN-05-1661.CrossRefPubMed
34.
Xu LH, Yang X, Craven RJ, Cance WG: The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ. 1998, 9 (12): 999-1005.PubMed
35.
Earley S, Plopper GE: Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells. Biochem Biophys Res Commun. 2006, 350 (2): 405-408. 10.1016/j.bbrc.2006.09.056.CrossRefPubMed
36.
Lulo J, Yuzawa S, Schlessinger J: Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2. Biochem Biophys Res Commun. 2009, 383 (3): 347-352. 10.1016/j.bbrc.2009.04.011.CrossRefPubMed
37.
38.
Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ: Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 2001, 15 (22): 2934-2939. 10.1101/gad.929901.CrossRefPubMedPubMedCentral
39.
Zhao J, Pestell R, Guan JL: Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. Mol Biol Cell. 2001, 12 (12): 4066-4077.CrossRefPubMedPubMedCentral
40.
Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY: MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene. 2003, 22 (9): 1381-1389. 10.1038/sj.onc.1206154.CrossRefPubMed
41.
Song H, Jin X, Lin J: Stat3 upregulates MEK5 expression in human breast cancer cells. Oncogene. 2004, 23 (50): 8301-8309. 10.1038/sj.onc.1208026.CrossRefPubMed
42.
Wang C, Xiao Y, Hu Z, Chen Y, Liu N, Hu G: PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma. FEBS Lett. 2008, 582 (18): 2793-2798. 10.1016/j.febslet.2008.07.009.CrossRefPubMed
43.
Li CM, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H, Szabolcs M, Klinakis A, Tycko B: PEG10 is a c-MYC target gene in cancer cells. Cancer Res. 2006, 66 (2): 665-672. 10.1158/0008-5472.CAN-05-1553.CrossRefPubMed
44.
Vie N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C, et al: Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer. 2008, 7: 14-18. 10.1186/1476-4598-7-14.CrossRefPubMedPubMedCentral
45.
Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, et al: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 2005, 65 (10): 4101-4117. 10.1158/0008-5472.CAN-05-0064.CrossRefPubMed
46.
Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G: Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas. 2008, 36 (2): 178-186. 10.1097/MPA.0b013e31815929fe.CrossRefPubMed
47.
Nyormoi O, Wang Z, Doan D, Ruiz M, McConkey D, Bar-Eli M: Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Mol Cell Biol. 2001, 21 (15): 4856-4867. 10.1128/MCB.21.15.4856-4867.2001.CrossRefPubMedPubMedCentral
48.
Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC: Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol. 1999, 189 (4): 514-520. 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9.CrossRefPubMed
49.
Pellikainen J, Kataja V, Ropponen K, Kellokoski J, Pietilainen T, Bohm J, Eskelinen M, Kosma VM: Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin Cancer Res. 2002, 8 (11): 3487-3495.PubMed
50.
Orso F, Penna E, Cimino D, Astanina E, Maione F, Valdembri D, Giraudo E, Serini G, Sismondi P, De Bortoli M, et al: AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. Faseb J. 2008, 22 (8): 2702-2714. 10.1096/fj.08-106492.CrossRefPubMed
51.
Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martin-Perez J: Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem. 2006, 281 (30): 20851-20864. 10.1074/jbc.M601570200.CrossRefPubMed
Metadata
Title
The direct effect of Focal Adhesion Kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis
Authors
Vita M Golubovskaya
Min Zheng
Li Zhang
Jian-Liang Li
William G Cance
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-280

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas

Research article

Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer

Research article

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia

Research article

IGF-I activates caspases 3/7, 8 and 9 but does not induce cell death in colorectal cancer cells

Research article

A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population

Research article

Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits